Escalon Medical Corp. Reports Modest Revenue Increase to $12.05 Million for Fiscal Year Ending June 30, 2025

Escalon Medical Corp. reported a modest increase in consolidated net revenue for the fiscal year ending June 30, 2025, totaling approximately $12.05 million, a rise of $64,000 or 0.5% compared to the previous year. This growth was primarily driven by a $114,000 increase in sales of Trek products, although it was partially offset by declines in sales from Sonomed products and AXIS revenue, which decreased by $33,000 and $17,000, respectively. The company's cost of revenue also improved, decreasing to $6.54 million, or 54.3% of total revenue, down from 57.0% in the prior year, reflecting a favorable change in product mix.

In terms of operational metrics, Escalon's employee headcount remained stable at 39 as of June 30, 2025. The company continues to focus on its core business of developing and distributing medical devices for ophthalmic applications, with significant investments in research and development, which increased by 9.4% to $753,000. This investment is aimed at enhancing existing products and introducing new offerings, particularly in the ultrasound ophthalmic equipment sector. The company has also maintained its commitment to regulatory compliance, having received necessary FDA approvals for its products.

Despite the slight revenue growth, Escalon faces ongoing financial challenges, including an accumulated deficit of approximately $68.4 million. The company has historically struggled with profitability, achieving net income in only two of the last five years. The recent fiscal year did see a net income of $105,525, a significant turnaround from a loss of $125,261 in the previous year. However, the company’s financial statements raise substantial doubt about its ability to continue as a going concern, primarily due to its history of operating losses and negative cash flows from operations.

Looking ahead, Escalon is actively monitoring market conditions, particularly the impact of recent tariffs on imports, which could affect its cost structure and profitability. The company is exploring potential partnerships and cost-cutting measures to enhance its financial stability. Management remains cautious about future growth, emphasizing the need for continued innovation and effective market strategies to navigate the competitive landscape of the ophthalmic medical device industry. The company’s stock trades on the OTCQB Market under the symbol "ESMC," and it has not paid cash dividends, opting instead to reinvest earnings for growth.